Navigation Links
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Date:11/15/2011

gn and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 


'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
2. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
3. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
4. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
5. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
6. GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
7. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available
10. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
11. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... has been pushed to the brink of extinction but ... the big questions which a Bristol academic addresses in his ... of Medicine at the University of Bristol, has produced the ... with fear: the story of polio explores the experiences of ... of the disease. , According to a review ...
(Date:6/19/2013)... 2013 Ultimate Medical Academy (UMA) participated ... broadcast on WFLA News Channel 8. Since its inaugural ... $84 million for All Children's Hospital in St. Petersburg, ... Years of Miracles," marked the second year UMA volunteered ... worked the phones during the Telethon, which raised a ...
(Date:6/19/2013)... Imprivata ®, a leading global provider of ... OneSign ® leads the single sign-on (SSO) category in ... Services report . CIOs and other healthcare executives iwere ... of its products and the quality of its customer ... integral to their long-term healthcare IT strategy. , ...
(Date:6/19/2013)... June 19, 2013 Maui'd Forever ... dedicated to being an effective and cost effective way ... They have partnered up with Tom Barefoot’s Tours providing ... on most of Hawaii’s activities. , They have just ... can get the lowest prices on their Hawaii activities. ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The producers of ... dates for Phoenix, Arizona. The city is located in ... Sun”. It has shed its frontier image and become an ... It is the fifth-largest city in the United States with ... industries. It offers residents a low cost-of-living, friendly business environment ...
Breaking Medicine News(10 mins):Health News:Paralysed with fear: The story of polio 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Viewpoints TV Announces June Air Dates for Phoenix, AZ 2
... in the treatment of strokes according to a report released in ... the cord blood could heal strokes almost 80% faster based on ... be worked out and the project itself is in a primitive ... R. Sanberg from the university of South Florida conducted the study. ...
... exclusive to the blessed. The less fortunate are those ... early morning headaches or serious daytime fatigue. Among the ... moderate form is commonly experienced. Sleep apnea is a ... Most individuals may have less severe sleep related breathing ...
... quake-devastated state of,Gujarat in India is now slowly coming ... different news channels and papers are busy increasing the,death ... state government and,the central government are now faced with ... hospitals are crammed with patients and doctors are,desperately needed ...
... have an eating disorder when compared with non-diabetic girls. ... than their prescribed dose of insulin in order to ... onset of diabetes related complications and are associated with ... diabetes could be the risk factor for developing eating ...
... at the just concluded Indian science congress in New Delhi ... combat anemia with iron fortification of crops. Almost 50% of ... anemic in India. While iron supplementation is expensive, fortification of ... anemia in people is fairly cheaper, scientists say. ,This ...
... related tissue experiences ischemia, a state of low oxygen supply ... / Reperfusion (IR) injury occurs during heart attacks. ,Understanding ... to save the damaged tissue and treat heart attack. During ... increases and acts like a common link between the pathways ...
Cached Medicine News:Health News:Doctors needed urgently in Gujarat 2Health News:Doctors needed urgently in Gujarat 3Health News:Doctors needed urgently in Gujarat 4
...
...
...
... The Premier Anterior Cervical Plate System ... screw translation along slots in the ... the distal end of the construct. ... has graft pre-compression features that enable ...
Medicine Products: